Review links linagliptin to lower kidney risk in diabetes

11/6/2012 | Medscape (free registration)

An analysis presented at Kidney Week 2012 showed type 2 diabetes patients who took linagliptin were 16% less likely to develop micro- and macroalbuminuria, chronic kidney disease and acute renal failure and showed lower risk of all-cause mortality compared with those in the placebo group.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ